Cantor Fitzgerald reiterates Acadia stock rating, cites Daybue growth

Cantor Fitzgerald, a major financial firm, is sticking with its current rating for Acadia Pharmaceuticals' stock, pointing to the promising growth of their drug Daybue. Essentially, they're saying Acadia's prospects look steady—or even improving—thanks to this key product.